Trehalose
CAS 99-20-7
Trehalose (CAS 99-20-7) is a Phase 3 pharmaceutical compound with 2 bioactivity targets and 1 adverse event association.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 19976.309999999998 nM | 1 | - |
| - | Kd | 36100 nM | 1 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| TREHALOSE | 1311373 | SU | MTHSPL |
| trehalose | 1311373 | SU | MTHSPL |
| trehalose | 1311373 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Trehalose used for in pharmaceutical contexts?
Trehalose (CAS 99-20-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Trehalose?
Trehalose has 1 DrugCentral/FAERS adverse event association. Rendered reaction terms include Papillary cystadenoma lymphomatosum. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Trehalose also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Trehalose with EU status "permitted".
What clinical phase is Trehalose in?
Trehalose is rendered with ChEMBL max phase 3.